Abbott wrapped up 2014 by completing its acquisition of Topera, a company that develops electrophysiology technologies to diagnose and treat patients with atrial fibrillation.
Abbott acquired all outstanding equity of Topera in late December for $250 million, and agreed to potential future payments based on performance milestones. Topera develops diagnostic catheter and mapping software to help electrophysiologists identify and target patient-specific rotors suspected in atrial fibrillation. The mapping procedure is used to facilitate catheter ablation therapy.
Abbott is based in Abbott Park, Ill., and Topera is in Menlo Park, Calif. The acquisition completes a deal that was initiated in October 2014.